Photys Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Induced Proximity PHICS Technology for Cardiometabolic Diseases
18 déc. 2024 07h30 HE
|
Photys Therapeutics, Incl
Photys and Novo Nordisk established a research collaboration to discover a new class of medicine for cardiometabolic diseases.
Vandria announces first subjects dosed in its first-in-human Phase 1 clinical trial of VNA-318 brain-penetrant mitophagy inducer
18 déc. 2024 03h00 HE
|
Vandria
LAUSANNE, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today...
BHIANT Celebrates Milestones in Workforce Development and Industry Collaboration, Sets Vision for 2025
17 déc. 2024 10h00 HE
|
BHIANT
DALLAS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The Biotechnology and Healthcare Industry Alliance of North Texas (BHIANT) proudly announces significant progress in workforce development and industry...
YPrime Commits to United Nations Global Compact, Pledging to Align its Sustainable Business Practices with UN Goals
17 déc. 2024 09h57 HE
|
Y-Prime, LLC
YPrime pledges to United Nations Global Compact, expanding its program of sustainable business practices.
Upstream Bio Appoints Allison Ambrose as General Counsel
17 déc. 2024 08h00 HE
|
Upstream Bio
Upstream appoints Allison Ambrose as General Counsel
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
17 déc. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
17 déc. 2024 06h30 HE
|
Silexion Therapeutics Corp
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
EyeDNA Therapeutics Receives Rare Pediatric Disease Designation from FDA for its Investigational Gene Therapy HORA-PDE6b for Patients with Retinal Dystrophy due to PDE6b Gene Mutations
17 déc. 2024 06h00 HE
|
Coave Therapeutics
PDE6b-related Retinitis Pigmentosa is a rare inherited retinal dystrophy affecting up to 3,000 people in the US Symptoms often start in childhood leading to blindness by midlife with no approved...
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
16 déc. 2024 16h30 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI...
Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike
16 déc. 2024 12h00 HE
|
Cannara Biotech (Québec) Inc.
Cannara announces its 2024 AGM will be virtual. Due to a postal strike. Proxy materials are online, and exemptions apply under CSA Blanket Order 51-913